Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CCX282-B for moderate-to-severe Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CCX282-B (CCR9 antagonist)

Snippet

Sponsor: Amgen | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED